Skip to main content
main-content

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The ATLAS trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

Read transcript

ASCO GU 2020 conference hub

Image Credits